BRNS
Income statement / Annual
Last year (2024), Barinthus Biotherapeutics plc's total revenue was $14.97 M,
an increase of 1,766.46% from the previous year.
In 2024, Barinthus Biotherapeutics plc's net income was -$61.07 M.
See Barinthus Biotherapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$14.97 M |
$802,000.00 |
$44.70 M |
$268,000.00 |
$4.82 M |
$6.87 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$0.55
|
| Gross Profit |
$14.97 M
|
$802,000.00
|
$44.70 M
|
$268,000.00
|
$4.82 M
|
$6.87 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$38.25 M
|
$41.41 M
|
$41.11 M
|
$16.37 M
|
$11.11 M
|
$29.97 M
|
| General & Administrative Expenses |
$29.67 M
|
$39.84 M
|
$6.39 M
|
$25.12 M
|
$10.48 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$29.67 M
|
$39.84 M
|
$6.39 M
|
$25.12 M
|
$10.48 M
|
$2.33 M
|
| Other Expenses |
$15.02 M
|
$3.46 M
|
$567,000.00
|
$332,000.00
|
$42,000.00
|
$0.00
|
| Operating Expenses |
$82.94 M
|
$84.72 M
|
$47.50 M
|
$41.49 M
|
$21.59 M
|
$32.30 M
|
| Cost And Expenses |
$82.94 M
|
$84.72 M
|
$47.50 M
|
$41.49 M
|
$21.59 M
|
$32.64 M
|
| Interest Income |
$2.68 M
|
$2.88 M
|
$3.10 M
|
$2,000.00
|
$267.06
|
$40,365.00
|
| Interest Expense |
$53,000.00
|
$28,000.00
|
$19,000.00
|
$2.67 M
|
$3.60 M
|
$133,299.00
|
| Depreciation & Amortization |
$5.80 M
|
$5.45 M
|
$5.54 M
|
$601,928.00
|
$210,019.00
|
$346,860.00
|
| EBITDA |
-$55.37 M |
-$71.07 M |
$6.40 M |
-$47.86 M |
-$14.14 M |
-$22.31 M |
| EBITDA Ratio |
-3.7
|
-88.61
|
0.12
|
-150.31
|
-3.43
|
-3.7
|
| Operating Income Ratio |
-4.54
|
-104.63
|
-0.09
|
-168.74
|
-4.16
|
-3.75
|
| Total Other Income/Expenses Net |
$6.74 M
|
$7.39 M
|
$4.89 M
|
-$5.92 M
|
$2.21 M
|
$2.98 M
|
| Income Before Tax |
-$61.23 M
|
-$76.52 M
|
$850,000.00
|
-$51.14 M
|
-$17.84 M
|
-$22.79 M
|
| Income Before Tax Ratio |
-4.09
|
-95.41
|
0.02
|
-190.82
|
-3.7
|
-3.32
|
| Income Tax Expense |
-$153,000.00
|
-$3.18 M
|
-$4.47 M
|
-$28,000.00
|
$95,000.00
|
-$2.02 M
|
| Net Income |
-$61.07 M
|
-$73.35 M
|
$5.34 M
|
-$50.87 M
|
-$17.71 M
|
-$20.82 M
|
| Net Income Ratio |
-4.08
|
-91.46
|
0.12
|
-189.79
|
-3.67
|
-3.03
|
| EPS |
-1.55 |
-1.91 |
0.14 |
-1.37 |
-371.62 |
0 |
| EPS Diluted |
-1.55 |
-1.91 |
0.14 |
-1.37 |
-371.62 |
0 |
| Weighted Average Shares Out |
$39.35 M
|
$38.39 M
|
$37.25 M
|
$37.19 M
|
$47,646.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$39.35 M
|
$38.39 M
|
$38.17 M
|
$37.19 M
|
$47,646.00
|
$0.00
|
| Link |
|
|
|
|
|
|
